Author Archives: Warren Woessner

Wide-Ranging Senate Bill Aims to Streamline Post-Grant Proceedings and Block Trolls

On Wednesday, Senator Coon—of 101 hearings fame—and five co-sponsors introduced the Stronger Patents Act in the Senate (“Support Technology & Research for Our Nation’s Growth and Economic Resilience”). About 22 of the bill’s 40 pages involve amendments to IPR, PGR … Continue reading

Posted in AIA Patent Reform, Inter Partes Review, Post-issuance procedures | Tagged , , , , , , , , , , | Leave a comment

Federal Circuit Denies En Banc Review of Athena v. Mayo

On July 3rd, the Fed. Cir. denied Athena’s petition for rehearing en banc. The three-page order is a 7/5 denial accompanied by more than 80 pages of concurrences and dissents. Concurring in various combinations are Judges Lourie, Hughes, Dyk, Reyna, … Continue reading

Posted in Patent Eligible Subject Matter, s. 101 | Tagged , , , , , , , , , | Leave a comment

Cutting Through the Patent Thicket – The Little Bill that Couldn’t

A bill was recently proposed to “reduce the improper issuance of patents that improperly extend the term of exclusivity afforded a new drug or biological product.” The bill would amend the patent statutes (s. 253 or title 35) for add … Continue reading

Posted in Drug Patent Term | Tagged , , , , , | Leave a comment

Senate Subcommittee Hearing of Patent Eligibility Wrap Up – Now What?

In my first post on the Subcommittee Hearings held last week, I noted the absence of many witnesses from the life science industry, as opposed to groups such as IPO, AIPLA, BIO, ACLU and PhMA. The third and final panel, … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | Leave a comment